Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.
about
Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocyclesArene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells.Unusual DNA binding modes for metal anticancer complexes.Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.Anticancer activity of metal complexes: involvement of redox processes.Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging PropertiesEffects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity.Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Antileukemic activity and cellular effects of rhodium(III) crown thiaether complexes.On the biological properties of alkynyl phosphine gold(I) complexes.The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure.Ru(II)/bisphosphine/diimine/amino acid complexes: diastereoisomerism, cytotoxicity, and inhibition of tumor cell adhesion to collagen type I
P2860
Q30623124-B385EC4E-5149-42FA-A7FE-D2B73E7C7B69Q34020456-190742EC-96AB-4C4D-BAD5-85B43439412EQ34071185-0AC11595-A3ED-4929-92AE-78D874611F18Q37424157-9B3DB14C-FE22-4934-BF19-279B08BDB91EQ37833099-2609DF15-CE98-4A4D-9C02-75897B3B38FFQ38753875-CF2DE780-714A-4A6B-BF82-1AB914C2A3CFQ38835381-AEBDD6FA-73D3-43BB-8329-FE6DFE4E32BEQ38838114-60F48A98-983C-45AD-9F9A-FAF0B4EEDA25Q39022215-D07D6B5A-B479-4DFC-98F6-F440347D0522Q39055996-ADEEDB9D-B4A2-4A2A-9F29-8AC1B01F75C9Q39220891-9D163FEA-2E17-4349-B67B-9BD55217C8BFQ51551365-8BE58ED7-5D48-44AE-A0F9-E000C9DCDA20Q52741196-E9C5C05D-E162-4D5A-BC94-C2E1E3E5AD90Q53503817-8FCBA5B8-75DC-42C5-BA1A-D6026EFFDB0CQ58860544-9C571790-C404-430D-A914-E886B8AA7C52
P2860
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiangiogenic properties of selected ruthenium
@nl
Antiangiogenic properties of s ...... t are nitric oxide scavengers.
@en
type
label
Antiangiogenic properties of selected ruthenium
@nl
Antiangiogenic properties of s ...... t are nitric oxide scavengers.
@en
prefLabel
Antiangiogenic properties of selected ruthenium
@nl
Antiangiogenic properties of s ...... t are nitric oxide scavengers.
@en
P2093
P2860
P356
P1476
Antiangiogenic properties of s ...... at are nitric oxide scavengers
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600906
P407
P577
2003-05-01T00:00:00Z